ERBB2 and non-small cell lung carcinoma: Poziotinib, an irreversible EGFR/HER2 inhibitor, produced an ORR of 27% [95% confidence interval (CI): 12%–46%], with an mPFS of 5.5 months [95% CI: 4.0–7.0 months] in NSCLC patients with HER2 exon 20 mutations.11